Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis

INTRODUCTION: Abrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis. METHODS: This post hoc analysis assessed the onset and depth of response of abrocitinib 100 or 200 mg in achieving the stringent outcome of ≥ 90% improvement from baseline in the Eczema Area and Severity Index score and Peak Pruritus Numerical Rating score of 0 to 1 (EASI-90 + PP-NRS0/1) in the JADE DARE (NCT04345367) and JADE COMPARE (NCT03720470) clinical trials, and previous dupilumab inadequate responders in the JADE EXTEND (NCT03422822) clinical trial. RESULTS: Higher proportions of patients achieved EASI-90 + PP-NRS0/1 with abrocitinib 200 mg (5.8%) versus dupilumab (1.1%) as early as week 2 in JADE DARE. In JADE COMPARE, 27.1% of patients treated with abrocitinib 200 mg achieved EASI-90 + PP-NRS0/1 compared with 20.2% with abrocitinib 100 mg, 15.5% with dupilumab, and 5.4% with placebo at week 16. Similar proportions of patients achieved this endpoint irrespective of baseline itch. Patients whose disease did not respond to dupilumab were able to achieve EASI-90 + PP-NRS0/1 with abrocitinib 200 or 100 mg in JADE EXTEND (16.7% and 18.5%, respectively). CONCLUSION: These findings suggest that minimal disease activity can be attained in patients with moderate-to-severe atopic dermatitis treated with abrocitinib, regardless of prior dupilumab exposure. TRIAL REGISTRATION: Clinicaltrials.gov identifiers: NCT04345367 (JADE DARE), NCT03720470 (JADE COMPARE), NCT03422822 (JADE EXTEND).